Effect of photobiomodulation as preventive treatment of diabetic foot ulcer: randomised, controlled, double-blind, clinical trial protocol

Introduction The prevention of diabetic foot ulcer (DFU) involves the classification of risk, systemic care, regular examinations, foot care, therapeutic education and adjunct treatments. Photobiomodulation (PBM) has been successfully administered for the healing of DFU and its preventive effects ha...

Full description

Saved in:
Bibliographic Details
Main Authors: Lara Jansiski Motta, Anna Carolina Ratto Tempestini Horliana, Kristianne Porta Santos Fernandes, Raquel Agnelli Mesquita-Ferrari, Sandra Kalil Bussadori, Roselene Lourenço, Silvana Torres Perez, Cinthya Cosme Gutierrez Duran, Alexandre Rocha Santos Padilha, Tainá Caroline dos Santos Malavazzi
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/1/e094594.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832590866249678848
author Lara Jansiski Motta
Anna Carolina Ratto Tempestini Horliana
Kristianne Porta Santos Fernandes
Raquel Agnelli Mesquita-Ferrari
Sandra Kalil Bussadori
Roselene Lourenço
Silvana Torres Perez
Cinthya Cosme Gutierrez Duran
Alexandre Rocha Santos Padilha
Tainá Caroline dos Santos Malavazzi
author_facet Lara Jansiski Motta
Anna Carolina Ratto Tempestini Horliana
Kristianne Porta Santos Fernandes
Raquel Agnelli Mesquita-Ferrari
Sandra Kalil Bussadori
Roselene Lourenço
Silvana Torres Perez
Cinthya Cosme Gutierrez Duran
Alexandre Rocha Santos Padilha
Tainá Caroline dos Santos Malavazzi
author_sort Lara Jansiski Motta
collection DOAJ
description Introduction The prevention of diabetic foot ulcer (DFU) involves the classification of risk, systemic care, regular examinations, foot care, therapeutic education and adjunct treatments. Photobiomodulation (PBM) has been successfully administered for the healing of DFU and its preventive effects have drawn the interest of researchers.Methods and analysis The purpose of the study is to assess the effect of PBM for the prevention of DFU through a randomised, controlled, double-blind, clinical trial. Individuals from 18 to 75 years of age of both sexes with type 2 diabetes mellitus (DM) at moderate to high risk of developing DFU will be randomly allocated to two groups of 32 participants each. The PBM group will wear a boot with 1344 light-emitting diodes (LEDs)—504 with a wavelength of 660 nm located on the sides of the boot (28.5 mW, 10 J per LED), 504 with a wavelength of 850 nm also on the sides of the boot (23 mW, 8 J per LED), 168 with a wavelength of 660 nm on the base of the boot (28.5 mW, 10 J per LED) and 168 with a wavelength of 850 nm also on the base of the boot (23 mW, 8 J per LED). The boot will be worn once a day for 6 min over 60 days and the participants will also receive therapeutic education. The control group will wear a non-therapeutic LED boot (sham) under the same conditions and will also receive therapeutic education. Assessments will be performed at the beginning of the study, after 30 days (clinical examination) and after 60 days (clinical examination, assessment of peripheral neuropathy (PN) and peripheral artery disease (PAD), blood and urine examinations and quality of life).Ethics and dissemination This protocol received approval from the Human Research Ethics Committee of Nove de Julho University and the Mandaqui Hospital Complex (certificate number: 66098522.0.3001.5511; final approval date: 22 June 2023). The findings will be published in a peer-reviewed journal.Trial registration number NCT06353568, ClinicalTrials.gov.
format Article
id doaj-art-184a440f56c34fbbbbdb0294ed2bbb02
institution Kabale University
issn 2044-6055
language English
publishDate 2025-01-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-184a440f56c34fbbbbdb0294ed2bbb022025-01-23T06:10:09ZengBMJ Publishing GroupBMJ Open2044-60552025-01-0115110.1136/bmjopen-2024-094594Effect of photobiomodulation as preventive treatment of diabetic foot ulcer: randomised, controlled, double-blind, clinical trial protocolLara Jansiski Motta0Anna Carolina Ratto Tempestini Horliana1Kristianne Porta Santos Fernandes2Raquel Agnelli Mesquita-Ferrari3Sandra Kalil Bussadori4Roselene Lourenço5Silvana Torres Perez6Cinthya Cosme Gutierrez Duran7Alexandre Rocha Santos Padilha8Tainá Caroline dos Santos Malavazzi9Biophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilBiophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilBiophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilBiophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilBiophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilBiophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilBiophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilBiophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilBiophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilBiophotonics Medicine, Universidade Nove de Julho, Sao Paulo, BrazilIntroduction The prevention of diabetic foot ulcer (DFU) involves the classification of risk, systemic care, regular examinations, foot care, therapeutic education and adjunct treatments. Photobiomodulation (PBM) has been successfully administered for the healing of DFU and its preventive effects have drawn the interest of researchers.Methods and analysis The purpose of the study is to assess the effect of PBM for the prevention of DFU through a randomised, controlled, double-blind, clinical trial. Individuals from 18 to 75 years of age of both sexes with type 2 diabetes mellitus (DM) at moderate to high risk of developing DFU will be randomly allocated to two groups of 32 participants each. The PBM group will wear a boot with 1344 light-emitting diodes (LEDs)—504 with a wavelength of 660 nm located on the sides of the boot (28.5 mW, 10 J per LED), 504 with a wavelength of 850 nm also on the sides of the boot (23 mW, 8 J per LED), 168 with a wavelength of 660 nm on the base of the boot (28.5 mW, 10 J per LED) and 168 with a wavelength of 850 nm also on the base of the boot (23 mW, 8 J per LED). The boot will be worn once a day for 6 min over 60 days and the participants will also receive therapeutic education. The control group will wear a non-therapeutic LED boot (sham) under the same conditions and will also receive therapeutic education. Assessments will be performed at the beginning of the study, after 30 days (clinical examination) and after 60 days (clinical examination, assessment of peripheral neuropathy (PN) and peripheral artery disease (PAD), blood and urine examinations and quality of life).Ethics and dissemination This protocol received approval from the Human Research Ethics Committee of Nove de Julho University and the Mandaqui Hospital Complex (certificate number: 66098522.0.3001.5511; final approval date: 22 June 2023). The findings will be published in a peer-reviewed journal.Trial registration number NCT06353568, ClinicalTrials.gov.https://bmjopen.bmj.com/content/15/1/e094594.full
spellingShingle Lara Jansiski Motta
Anna Carolina Ratto Tempestini Horliana
Kristianne Porta Santos Fernandes
Raquel Agnelli Mesquita-Ferrari
Sandra Kalil Bussadori
Roselene Lourenço
Silvana Torres Perez
Cinthya Cosme Gutierrez Duran
Alexandre Rocha Santos Padilha
Tainá Caroline dos Santos Malavazzi
Effect of photobiomodulation as preventive treatment of diabetic foot ulcer: randomised, controlled, double-blind, clinical trial protocol
BMJ Open
title Effect of photobiomodulation as preventive treatment of diabetic foot ulcer: randomised, controlled, double-blind, clinical trial protocol
title_full Effect of photobiomodulation as preventive treatment of diabetic foot ulcer: randomised, controlled, double-blind, clinical trial protocol
title_fullStr Effect of photobiomodulation as preventive treatment of diabetic foot ulcer: randomised, controlled, double-blind, clinical trial protocol
title_full_unstemmed Effect of photobiomodulation as preventive treatment of diabetic foot ulcer: randomised, controlled, double-blind, clinical trial protocol
title_short Effect of photobiomodulation as preventive treatment of diabetic foot ulcer: randomised, controlled, double-blind, clinical trial protocol
title_sort effect of photobiomodulation as preventive treatment of diabetic foot ulcer randomised controlled double blind clinical trial protocol
url https://bmjopen.bmj.com/content/15/1/e094594.full
work_keys_str_mv AT larajansiskimotta effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol
AT annacarolinarattotempestinihorliana effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol
AT kristianneportasantosfernandes effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol
AT raquelagnellimesquitaferrari effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol
AT sandrakalilbussadori effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol
AT roselenelourenco effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol
AT silvanatorresperez effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol
AT cinthyacosmegutierrezduran effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol
AT alexandrerochasantospadilha effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol
AT tainacarolinedossantosmalavazzi effectofphotobiomodulationaspreventivetreatmentofdiabeticfootulcerrandomisedcontrolleddoubleblindclinicaltrialprotocol